M. Varella‐Garcia

发表

Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014 .

Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

F. Cappuzzo, M. Varella‐Garcia, R. Doebele, 2012, Clinical Cancer Research.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014, The New England journal of medicine.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

M. Varella‐Garcia, B. Solomon, D. Camidge, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Manuel Hidalgo, Aik Choon Tan, Jordy Coffa, 2008, Cancer research.

Tackling the Human Cell Line and Tissue Misidentification Problem Is Needed for Reproducible Biomedical Research

C. Korch, M. Varella‐Garcia, M. Varella-Garcia, 2018, Advances in Molecular Pathology.

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

P. Jänne, F. Cappuzzo, K. Okuno, 2011, Science Translational Medicine.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2011, The Lancet. Oncology.

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.

E. Crawford, P. Sunpaweravong, M. Varella‐Garcia, 2004, Urologic oncology.

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract

Fadlo R. Khuri, Michael R. Rossi, Guojing Zhang, 2015, Therapeutic advances in medical oncology.

Adult lung side population cells have mesenchymal stem cell potential.

M. Varella‐Garcia, S. Majka, E. Burnham, 2008, Cytotherapy.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer

A. Iafrate, A. Shaw, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium.

K. Horwitz, M. Varella‐Garcia, J. Harrell, 2006, Cancer research.

Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

Humam Kadara, Diane D. Liu, Diane D Liu, 2011, Clinical Cancer Research.

Biologic and Genetics Aspects of Chagas Disease at Endemic Areas

M. Varella‐Garcia, A. E. Silva, M. T. D. de Azeredo-Oliveira, 2012, Journal of tropical medicine.

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

E. Crawford, M. Varella‐Garcia, A. Barqawi, 2004, The Prostate.

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

M. Varella‐Garcia, A. Tan, S. Eckhardt, 2012, Clinical Cancer Research.

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

M. Varella‐Garcia, P. Elvin, D. Gao, 2010, Clinical Cancer Research.

Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer.

S. Lam, T. Byers, Y. Miller, 2009, ATS 2009.

Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines

M. Lucia, M. Varella‐Garcia, G. Miller, 2003, The Prostate.

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

M. Varella‐Garcia, H. Selby, A. Tan, 2013, Front. Pharmacol..

TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin.

C. Korch, M. Varella‐Garcia, G. Miller, 2001, Cancer research.

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

M. Ladanyi, A. Iafrate, M. Kris, 2015, Cancer.

Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line

Ying Wang, Amanda Capes-Davis, Edward C Burnett, 2017, International journal of cancer.

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

A. Carrato, M. Hidalgo, M. Varella‐Garcia, 2011, Critical reviews in oncology/hematology.

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

M. Kris, M. Arcila, M. Varella‐Garcia, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

S. Ou, M. Varella‐Garcia, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2002, Clinical breast cancer.

Prognostic patterns in the histopathology of pulmonary adenocarcinoma.

W. Franklin, M. Varella‐Garcia, D. Aisner, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Roy S Herbst, Diane D. Liu, Diane D Liu, 2007, Clinical Cancer Research.

Molecular characterization of human prostate carcinoma cell lines

C. Korch, M. Lucia, M. Varella‐Garcia, 2003, The Prostate.

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, M. Ladanyi, A. Iafrate, 2013 .

Adjusting interphase FISH results in epithelial tissue sections to whole cell complement.

W. Franklin, M. Varella‐Garcia, M. Berezuk, 2001, Analytical and quantitative cytology and histology.

Complex cytogenetic rearrangement in a case of unicameral bone cyst.

M. Varella‐Garcia, S. A. Vayego, O. J. De Conti, 1996, Cancer genetics and cytogenetics.

SIX1 (sine oculis homeobox homolog 1) (mammalian)

H. Ford, M. Varella‐Garcia, A. Patrick, 2011 .

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Christine H Chung, Loris McGavran, Joel Parker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

A. Iafrate, M. Socinski, S. Ou, 2014 .

Application of SNP Microarrays to the Genome-Wide Analysis of Chromosomal Instability in Premalignant Airway Lesions

Y. Miller, W. Franklin, M. Varella‐Garcia, 2013, Cancer Prevention Research.

NTRK2 gene fusions are uncommon in pilocytic astrocytoma

M. Varella‐Garcia, R. Reis, C. Scapulatempo-Neto, 2022, Molecular Biology Reports.

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.

K. Kelly, John D. Mitchell, W. Franklin, 2007, The Lancet. Oncology.

Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.

M. Varella‐Garcia, G. Noon, S. Erzurum, 2010, American journal of respiratory and critical care medicine.

EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib.

F. Hirsch, T. Mitsudomi, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions

Y. Kluger, D. Wheeler, J. Minna, 2016, Oncotarget.

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

F. Hirsch, P. Bunn, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.

F. Hirsch, P. Bunn, D. Gandara, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Kenneth L. Jones, P. Bunn, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

F. Hirsch, C. Watkins, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment

F. Hirsch, P. Bunn, D. Gandara, 2005 .

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

I. Wistuba, M. Varella‐Garcia, C. Moran, 2008, Cancer Prevention Research.

Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

W. Franklin, M. Varella‐Garcia, R. Doebele, 2013, Cancer.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

M. Kris, G. Sica, I. Wistuba, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of the National Cancer Institute.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

M. Socinski, R. Kurek, F. Hirsch, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126)

F. Hirsch, P. Bunn, D. Gandara, 2005 .

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

M. Varella‐Garcia, M. Varella-Garcia, Marileila Varella-Garcia, 2006, Diagnostic pathology.

J. Minna, A. Gazdar, P. Bunn, 2006 .

Gefitinib sensitivity in non-small cell lung cancer (NSCLC) cell lines associates with mutation and amplification of the epidermal growth factor receptor (EGFR) gene

J. Minna, M. Peyton, A. Gazdar, 2005 .

Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)

F. Hirsch, C. Watkins, P. Bunn, 2007 .

Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

Advances in Brief TSU-Pr 1 and JCA-1 Cells Are Derivatives of T 24 Bladder Carcinoma Cells and Are Not of Prostatic Origin 1

C. Korch, M. Varella‐Garcia, G. Miller, 2001 .

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients

M. Varella‐Garcia, F. Andreoni, C. Gambacorti-Passerini, 2005, Leukemia.

Glioblastomas in the older old.

M. Varella‐Garcia, K. Lillehei, B. Kleinschmidt-DeMasters, 2005, Archives of pathology & laboratory medicine.

EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer

P. Jänne, F. Cappuzzo, W. Franklin, 2007 .

Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.

M. Varella‐Garcia, A. Fett-Conte, M. Ruiz, 2008, Genetics and molecular research : GMR.

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Carmen Behrens, Ignacio I Wistuba, K. Aldape, 2009, Clinical Cancer Research.

Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, J. Engelman, 2013 .

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

A. Marchetti, F. Buttitta, F. Cappuzzo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites.

Y. Miller, P. Bunn, W. Franklin, 1996, American journal of respiratory cell and molecular biology.

Malformations detected by abdominal ultrasound in children with congenital heart disease.

M. Varella‐Garcia, R. Rosa, G. Paskulin, 2012, Arquivos brasileiros de cardiologia.

Human pulmonary chimerism after hematopoietic stem cell transplantation.

M. Varella‐Garcia, E. Shpall, K. Brown, 2003, American journal of respiratory and critical care medicine.

Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

M. Lucia, M. Varella‐Garcia, A. van Bokhoven, 2011, Urology.

De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific

M. Varella‐Garcia, D. Klemm, S. Majka, 2010, Proceedings of the National Academy of Sciences.

[Oculo-auriculo-vertebral spectrum in patients with congenital heart defects].

M. Varella‐Garcia, C. Pilla, R. Rosa, 2010, Arquivos brasileiros de cardiologia.

Suppression of leukemia development caused by PTEN loss

M. Varella‐Garcia, Hubing Shi, Wei Guo, 2011, Proceedings of the National Academy of Sciences.

The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss

M. Varella‐Garcia, J. DeGregori, J. Jensen, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Karyotypic characteristics of human uterine leiomyoma and myometrial cell lines following telomerase induction.

M. Varella‐Garcia, D. Dixon, Linda Yu, 2006, Cancer genetics and cytogenetics.

New complex chromosome abnormalities in multiple myeloma associated with a poor prognosis: a case report.

M. Varella‐Garcia, A. Fett-Conte, A. B. Carvalho-Salles, 2012, Leukemia research.

Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.

M. Varella‐Garcia, S. Saichaemchan, W. Ariyawutyakorn, 2016, Current molecular medicine.

RET rearrangements detected by FISH in "pan-negative" lung adenocarcinoma.

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013 .

HIV-1 Tat increases oxidant burden in the lungs of transgenic mice.

M. Varella‐Garcia, S. Flores, A. Cota-Gomez, 2011, Free radical biology & medicine.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.

M. Varella‐Garcia, C. Kruse, G. Gomez, 2006, Cancer genetics and cytogenetics.

Malignancy detection by molecular cytogenetics in clinically normal mucosa adjacent to head and neck tumors.

A. Meyers, M. Varella‐Garcia, J. Barrera, 1998, Archives of otolaryngology--head & neck surgery.

Pre‐clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization

M. Varella‐Garcia, A. Sandberg, L. Mcgavran, 1998, Genes, chromosomes & cancer.

Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

A. Iafrate, A. Shaw, B. Yeap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interstitial long-arm deletion of chromosome 7 and ectrodactyly.

M. Varella‐Garcia, E. Tajara, A. C. Gusson, 1989, American journal of medical genetics.

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

P. Jänne, J. Engelman, K. Zejnullahu, 2011 .

Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment

A. Jimeno, M. Hidalgo, M. Varella‐Garcia, 2007 .

Assessing residual leukemia through fluorescence in situ hybridization

M. Varella‐Garcia, M. Varella-Garcia, 1998 .

Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients

P. Jänne, F. Cappuzzo, M. Varella‐Garcia, 2008 .

Molecular and Cytogenetic Analyses on Brazilian Youths with Pervasive Developmental Disorders

M. Varella‐Garcia, A. E. Silva, A. Fett-Conte, 2002, Journal of autism and developmental disorders.

Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

FISHing for lung cancer: Promising findings using multi-targeted interphase fluorescence in situ hybridization (FISH) for lung cancer detection in sputum

T. Byers, Y. Miller, F. Hirsch, 2007 .

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience.

W. Franklin, M. Varella‐Garcia, R. Doebele, 2016, Archives of pathology & laboratory medicine.

Defining the spectrum and "overlap" of HER2 aberrations in lung cancers: Associations of HER2 protein overexpression, HER2 amplification, and HER2 mutation.

M. Kris, M. Arcila, M. Varella‐Garcia, 2015 .

Macrothrombocytopenia as diagnosis predictor of 22q11 deletion syndrome among patients with congenital heart defects

M. Varella‐Garcia, M. Fiegenbaum, P. Trevisan, 2015, American journal of medical genetics. Part A.

Screening for 22q11 deletion syndrome among patients with congenital heart defects.

M. Varella‐Garcia, P. Trevisan, R. Rosa, 2014, Sao Paulo medical journal = Revista paulista de medicina.

Atypical chromosome abnormalities in acute myeloid leukemia type M4

M. Varella‐Garcia, A. Fett-Conte, Octávio Ricci-Júnior, 2007 .

Translocation (11;19)(q23;p13.3) associated with a novel t(5;16) (q13;q22) in a patient with acute myelocytic leukemia.

M. Varella‐Garcia, A. Fett-Conte, M. Ruiz, 2003, Cancer genetics and cytogenetics.

A dup(17)(p11.2p11.2) detected by fluorescence in situ hybridization in a boy with Alport syndrome.

M. Varella‐Garcia, M. Balarin, V. L. G. da Silva Lopes, 1999, American journal of medical genetics.

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

Michael Peyton, John D. Minna, Yang Xie, 2009, PloS one.

O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib

F. Hirsch, P. Bunn, W. Franklin, 2005 .

Clinical Activity of Crizotinib in Patients with Advanced Non-small Cell Lung Cancer Harboring ROS1 Gene Rearrangement

A. Iafrate, M. Varella‐Garcia, P. Stephenson, 2012 .

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

A. Jimeno, U. Rix, M. Varella‐Garcia, 2017, Cancer research.

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Tatiana G. Kutateladze, Dara L. Aisner, Lynn E. Heasley, 2012, Clinical Cancer Research.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of individuals at high risk for head and neck carcinogenesis using chromosome aneuploidy detected by fluorescence in situ hybridization.

A. Meyers, M. Varella‐Garcia, J. Barrera, 1999, Mutation research.

XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

A. Jimeno, M. Varella‐Garcia, A. Tan, 2015, Oncogene.

Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

M. Varella‐Garcia, M. Skokan, Mark Jones, 2013, Cytotherapy.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

M. Varella‐Garcia, L. Crinò, R. Chiari, 2013, Cancer Chemotherapy and Pharmacology.

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Chan Zeng, Anna E Barón, F. Hirsch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

G. Scagliotti, F. Hirsch, W. Franklin, 2003, Lung cancer.

Epidermal G rowth F actor R eceptor i n N on-Small-Cell L ung Carcinomas: C orrelation B etween G ene C opy N umber a nd Protein E xpression a nd I mpact o n P rognosis

F. Hirsch, P. Bunn, W. Franklin, 2003 .

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Dara L Aisner, Antonio Jimeno, P. Stephens, 2015, Cancer discovery.

Assessment of biologically aggressive, recurrent glandular odontogenic cysts for mastermind‐like 2 (MAML2) rearrangements: histopathologic and fluorescent in situ hybridization (FISH) findings in 11 cases

M. Varella‐Garcia, R. Greer, P. Freedman, 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas

M. Varella‐Garcia, R. Reis, C. Scapulatempo-Neto, 2015, Journal of neuropathology and experimental neurology.

Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer

L. Garraway, P. Stephens, P. Jänne, 2013, Nature Medicine.

Clinical and Molecular Characterization of Adult Glioblastomas in Southern Brazil

M. Varella‐Garcia, P. Trevisan, R. Rosa, 2019, Journal of neuropathology and experimental neurology.

Establishment and characterization of a human glioblastoma multiforme cell line.

M. Varella‐Garcia, A. Kubar, O. Yildiz, 1998, Cancer genetics and cytogenetics.

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

F. Cappuzzo, M. Varella‐Garcia, L. Bemis, 2006, The New England journal of medicine.

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

F. Hirsch, P. Bunn, W. Franklin, 2002, British Journal of Cancer.

Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification.

S. Weed, M. Varella‐Garcia, Lin Chen, 2006, Cancer research.

p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer

A. Marchetti, G. Alí, G. Fontanini, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

M. Varella‐Garcia, H. Selby, A. Tan, 2012, Clinical Cancer Research.

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

Calum MacAulay, John D. Minna, David S. Shames, 2009, PloS one.

Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation

M. Varella‐Garcia, M. Iruela-Arispe, W. Guo, 2008, Nature.

Pathology, Biomarkers, and Molecular Diagnostics

P. Bunn, W. Franklin, M. Varella‐Garcia, 2020 .

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

M. Varella‐Garcia, R. Supino, C. Gambacorti-Passerini, 2000, Blood.

Interphase Cytogenetics Using Fluorescence In Situ Hybridization: An Overview Of Its Application To Diffuse And Solid Tissue

Christine Hackel, Marileila Varella-Garcia, M. Varella‐Garcia, 1997 .

A panel of partial chromosome paints and YAC probes specific for human chromosome 2

N. Archidiacono, M. Rocchi, M. Varella‐Garcia, 1998, Somatic cell and molecular genetics.

Structural aberration of the X chromosome in a patient with gonadal dysgenesis: an approach to karyotype-phenotype correlation.

M. Varella‐Garcia, E. Tajara, A. Gagliardi, 1981, Journal of medical genetics.

Molecular Profiling of a Rare Rosette-Forming Glioneuronal Tumor Arising in the Spinal Cord

B. Scheithauer, M. Varella‐Garcia, R. Reis, 2015, PloS one.

Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization.

Y. Miller, F. Hirsch, L. Morrison, 2003, The Journal of molecular diagnostics : JMD.

Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

S. Lam, T. Byers, Y. Miller, 2008, American journal of respiratory and critical care medicine.

Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer.

T. Byers, Y. Miller, F. Hirsch, 2004, Cancer Detection and Prevention.

Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression

Brian C. Jackson, A. Jimeno, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer

S. Lam, T. Byers, Y. Miller, 2009, PloS one.

Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.

Y. Miller, F. Hirsch, W. Franklin, 2007, American journal of respiratory and critical care medicine.

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Robert Gentleman, Florian Gnad, John D. Minna, 2012, Nature Genetics.

Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies

M. Varella‐Garcia, B. Cho, M. Varella-Garcia, 2018 .

MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib

F. Cappuzzo, M. Varella‐Garcia, R. Gemmill, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

M. Varella‐Garcia, S. Saichaemchan, W. Ariyawutyakorn, 2016, Journal of Cancer.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

S. Asthana, E. Collisson, J. Riess, 2015, Nature Medicine.

Predictive Biomarkers and Personalized Medicine Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non – Small Cell Lung Cancer

W. Franklin, M. Varella‐Garcia, R. Doebele, 2012 .

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

R. Camidge, M. Varella‐Garcia, R. Doebele, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Eliot Y. Zhu, M. Varella‐Garcia, K. Davies, 2017, The Journal of molecular diagnostics : JMD.

ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers

Dara L Aisner, Nathan Schulte, J. Mariadason, 2013, Molecular Cancer Research.

Inter‐ and intra‐tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas

A. Jimeno, M. Varella‐Garcia, S. Karam, 2019, Molecular carcinogenesis.

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.

M. Varella‐Garcia, Jihye Kim, A. Tan, 2016, Journal of visualized experiments : JoVE.

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

A. Jimeno, E. Lam, M. Varella‐Garcia, 2014, Clinical Cancer Research.

Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer

Y. Miller, J. Siegfried, W. Franklin, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

E. Berns, A. Jimeno, D. Lambrechts, 2015, Targeted Oncology.

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

W. Lam, M. Peyton, A. Gazdar, 2017, Oncotarget.

Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques

M. Varella‐Garcia, A. E. Silva, M. F. Bellini, 2010, Genetics and molecular biology.

The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.

Edward S. Kim, M. Tsuboi, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization

M. Varella‐Garcia, L. Andrade, J. K. Heinrich, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013, PloS one.

Chromosomal and genomic changes in lung cancer

M. Varella‐Garcia, M. Varella-Garcia, 2010, Cell adhesion & migration.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Jeffrey W. Clark, A. Iafrate, S. Fox, 2012, The Lancet. Oncology.

Chromosomal Imbalances Are Uncommon in Chagasic

M. Varella‐Garcia, A. E. Silva, A. J. Manzato, 2009 .

An Anaplastic Lymphoma Kinase Immunohistochemistry–Negative but Fluorescence In Situ Hybridization–Positive Lung Adenocarcinoma Is Resistant to Crizotinib

T. Pugh, M. Tsao, M. Varella‐Garcia, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

S. C. Wang, A. Iafrate, A. Shaw, 2019 .

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

M. Varella‐Garcia, L. Crinò, V. Ludovini, 2015, American journal of clinical oncology.

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

K. Baggerly, G. Mills, K. Shaw, 2017, Clinical Cancer Research.

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

P. Sunpaweravong, W. Franklin, M. Varella‐Garcia, 2005, Journal of Cancer Research and Clinical Oncology.

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

F. Cappuzzo, M. Varella‐Garcia, D. Eberhard, 2009, Journal of Clinical Pathology.

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

F. Cappuzzo, F. Hirsch, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013 .

Title : The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas

A. Jimeno, M. Varella‐Garcia, A. Tan, 2013 .

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

W. Lam, J. Minna, J. Soh, 2009, International journal of cancer.

Widely used prostate carcinoma cell lines share common origins

C. Korch, M. Varella‐Garcia, G. Miller, 2001, The Prostate.

Intrachromosomal distribution of telomeric repeats in Eumops glaucinus and Eumops perotis (Molossidae, Chiroptera)

M. Varella‐Garcia, E. Morielle-Versute, V. A. Taddei, 2000, Chromosome Research.

Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease

P. Jänne, M. Scorsetti, M. Varella‐Garcia, 2014, PloS one.

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose‐ and sequence‐dependent manner

M. Varella‐Garcia, D. Raben, T. Flaig, 2009, BJU international.

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer

W. Franklin, M. Varella‐Garcia, R. Doebele, 2013, Cancer.

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer

M. Varella‐Garcia, R. Doebele, A. Baron, 2012, Cancer.

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

F. Cappuzzo, F. Hirsch, T. Boggon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

R. Herbst, F. Hirsch, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Clinical Cancer Research.

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

M. Ladanyi, A. Iafrate, M. Kris, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Detection of Chromosomal Aneusomy by Fluorescence In situ Hybridization in Sputum Predicts Lung Cancer Incidence

T. Byers, Y. Miller, F. Hirsch, 2010, Cancer Prevention Research.

Identification of common fragile sites in chromosomes of 2 species of bat (Chiroptera, Mammalia)

M. Varella‐Garcia, E. Morielle-Versute, 1994, Genetics Selection Evolution.

A survey of cytogenetic data on Brazilian bats

M. Varella‐Garcia, E. Morielle-Versute, V. A. Taddei, 1989 .

T-cell apoptosis in HIV-1–infected individuals receiving highly active antiretroviral therapy

M. Varella‐Garcia, R. Hromas, J. Strauchen, 2001 .

Gene amplification is a mechanism of Six1 overexpression in breast cancer.

H. Ford, M. Varella‐Garcia, R. Coletta, 2005, Cancer research.

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

A. Jimeno, F. Hirsch, M. Varella‐Garcia, 2013, Molecular oncology.

Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

P. Jänne, F. Cappuzzo, M. Varella‐Garcia, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2014 .

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Kenneth L. Jones, M. Varella‐Garcia, R. Doebele, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Kinase gene fusions in defined subsets of melanoma

Jennifer D. Hintzsche, Carol Amato, Eric Seelenfreund, 2017, Pigment cell & melanoma research.

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Marie C. South, F. Hirsch, P. Bunn, 2009, Clinical and translational science.

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

M. Varella‐Garcia, R. Doebele, A. Tan, 2017, Molecular Cancer Therapeutics.

Activation of RAS family members confers resistance to ROS1 targeting drugs

M. Varella‐Garcia, R. Doebele, R. Dziadziuszko, 2014, Oncotarget.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

P. Stephens, M. Cronin, F. Hirsch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer

P. Stephens, M. Cronin, F. Hirsch, 2012 .

Finding ALK-positive lung cancer: what are we really looking for?

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

W. Franklin, M. Varella‐Garcia, R. Doebele, 2010, Clinical Cancer Research.

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

M. Varella‐Garcia, D. Aisner, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is FISH floating or still swimming in the lung cancer ocean?

M. Varella‐Garcia, D. Camidge, F. Cappuzzo, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

F. Cappuzzo, F. Hirsch, E. Duffield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.

Jeffrey W. Clark, K. Ching, J. Christensen, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Chan Zeng, Adi Gazdar, J. Minna, 2006, Clinical Cancer Research.

Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

A. Thorburn, M. Varella‐Garcia, Xiaoping Yang, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Diphtheria Toxin – Epidermal Growth Factor Fusion Protein DAB 389 EGF for the Treatment of Bladder Cancer

A. Thorburn, M. Varella‐Garcia, Xiaoping Yang, 2012 .

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study

M. Moroni, V. Torri, F. Cappuzzo, 2011, Journal of Clinical Pathology.

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

P. Bunn, W. Franklin, M. Varella‐Garcia, 2012, Cancer.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers are here to stay for clinical research and standard care.

F. Hirsch, P. Bunn, W. Franklin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

W. Franklin, M. Varella‐Garcia, R. Doebele, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anterior laryngeal membrane and 22q11 deletion syndrome

M. Varella‐Garcia, R. Rosa, G. Paskulin, 2011, Brazilian journal of otorhinolaryngology.

[22q11.2 deletion syndrome: importance of clinical evaluation and FISH analysis].

M. Varella‐Garcia, C. Ricachinevsky, R. Rosa, 2009, Revista da Associacao Medica Brasileira.

22q11.2 deletion syndrome in patients admitted to a cardiac pediatric intensive care unit in Brazil

M. T. Hertz, M. Varella‐Garcia, C. Ricachinevsky, 2008, American journal of medical genetics. Part A.

Tetrasomy 15q11-q13 identified by fluorescence in situ hybridization in a patient with autistic disorder.

M. Varella‐Garcia, E. Goloni-Bertollo, A. E. Silva, 2002, Arquivos de neuro-psiquiatria.

Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2012 .

Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy.

K. Coombes, Jing Wang, J. Minna, 2011, Cancer research.

Partial trisomy 12q24.31----qter.

M. Varella‐Garcia, E. Tajara, A. C. Gusson, 1985, Journal of medical genetics.

Trisomy 8 syndrome.

M. Varella‐Garcia, E. Tajara, A. Gagliardi, 1978, Journal of medical genetics.

Adult recurrent pilocytic astrocytoma: Clinical, histopathological and molecular study.

M. Varella‐Garcia, A. Saâd, N. Mama, 2015, Neuro-Chirurgie.

Short communication Translocation (11;19)(q23;p13.3) associated with a novel t(5;16) (q13;q22) in a patient with acute myelocytic leukemia

M. Varella‐Garcia, A. Fett-Conte, M. Ruiz, 2003 .

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

C. Korch, F. Hirsch, M. Varella‐Garcia, 2010, Clinical Cancer Research.

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

I. Thompson, P. Goodman, C. Tangen, 2014, Urology.

ALDH+ tumor‐initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ‐secretase inhibitor and irinotecan in colorectal cancer

M. Varella‐Garcia, D. Gao, A. Tan, 2012, Molecular oncology.

HER2/neu expression in malignant lung tumors.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Sister-chromatid exchanges in beta-thalassaemic patients under conditions of in vivo and in vitro depletion of folic acid.

M. Varella‐Garcia, A. J. Manzato, A. E. Silva, 1992, Mutation research.

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

A. Jimeno, M. Varella‐Garcia, D. Gao, 2016, International journal of cancer.

Chromosomal aneuploidy as a predictor for poor outcome in patients with head and neck cancer.

M. Varella‐Garcia, J. Barrera, M. Varella-Garcia, 2001, Archives of otolaryngology--head & neck surgery.

Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy.

M. Varella‐Garcia, M. Varella-Garcia, 2003, The oncologist.

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme

S. Frye, M. Varella‐Garcia, J. Kowalski, 2016, PloS one.

Demographic studies in a Brazilian population of Arabian origin.

M. Varella‐Garcia, 1976, Social biology.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

F. Hirsch, E. Duffield, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorescence In situ Hybridization Subgroup Analysis ofTRIBUTE , a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non ^ Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008 .

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2006, Clinical Cancer Research.

AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels

A. Gazdar, F. Hirsch, P. Bunn, 2006 .

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer

F. Hirsch, M. Varella‐Garcia, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

F. Hirsch, M. Varella‐Garcia, D. Aisner, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines

M. Varella‐Garcia, B. Kleinschmidt-DeMasters, G. Owens, 1998, In Vitro Cellular & Developmental Biology - Animal.

NTRK1 gene fusions as a novel oncogene target in lung cancer.

P. Stephens, P. Jänne, D. Lipson, 2013 .

Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

S. C. Wang, Jeffrey W. Clark, A. Shaw, 2016 .

De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue

M. Varella‐Garcia, W. Kohrt, D. Klemm, 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Congenital heart disease in Southern Brazil: potential impact and prevention.

M. Varella‐Garcia, P. Trevisan, R. Rosa, 2015, International journal of cardiology.

Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.

H. Ford, M. Varella‐Garcia, R. Coletta, 2008, Cancer research.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort

F. Hirsch, T. Mitsudomi, P. Bunn, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

F. Hirsch, A. Armour, M. Varella‐Garcia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Biomarkers and Personalized Medicine Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

M. Varella‐Garcia, H. Selby, A. Tan, 2012 .

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.

M. Varella‐Garcia, D. Camidge, Joel P Womack, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

F. Cappuzzo, P. Bunn, W. Franklin, 2010 .

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer

R. Camidge, M. Varella‐Garcia, R. Doebele, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008, Clinical Cancer Research.

Role of hypocalcemia in identification of 22q11 deletion syndrome among patients with congenital heart defects.

M. Varella‐Garcia, M. Fiegenbaum, P. Trevisan, 2014, International journal of cardiology.

RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)--Association between EGFR gene copy number and patients' outcome

W. Curran, H. Choy, F. Hirsch, 2008 .

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

F. Hirsch, K. Kelly, P. Bunn, 2006, Clinical Cancer Research.

Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients.

W. Franklin, M. Varella‐Garcia, R. Doebele, 2012 .

547 Complex abnormalities involving chromosomal regions 3p and 9p in non-small cell lung cancer (NSCLC) revealed by fluorescence in situ hybridization (FISH)

Marshall W. Anderson, W. Franklin, M. Varella‐Garcia, 1997 .